Vol. 5 No. 6 (2025)
Reimbursement Recommendations

Isatuximab (Sarclisa)

decorative image of the issue cover

Published June 13, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Sarclisa be reimbursed by public drug plans for the treatment of patients with newly diagnosed multiple myeloma (MM) who are not eligible for autologous stem cell transplant (ASCT) if certain conditions are met.
  • Sarclisa should only be covered to treat patients who have newly diagnosed MM and who have not received any treatment for their disease. Patients also have to be unable to receive a stem cell transplant and should have a good performance status.
  • Sarclisa should only be reimbursed in combination with bortezomib-lenalidomide-dexamethasone (VRd) and if it is prescribed by clinicians with expertise in MM. The total cost of Sarclisa in combination with VRd should be negotiated so that it does not exceed the total drug program cost associated with daratumumab-lenalidomide-dexamethasone (DRd).